RADIOPHARM THERANOSTICS LIMITED

RADIOPHARM THERANOSTICS LIMITED (ASX: RAD)

Radiopharm Theranostics has completed a positive pre-IND meeting with the U.S. FDA for F18-pivalate (RAD 101), a radiopharmaceutical product.
The company will file an IND application to initiate a multi-center trial for imaging brain metastasis in Q3 2023 and aims to have the first patient dosed by the end of the year.
RAD 101 is a novel imaging agent with potential benefits for monitoring cerebral metastasis in high unmet medical need areas.

2023-05-29 11:25:00

Radiopharm Theranostics receives FDA Orphan Drug Designation for Ga68-Trivehexin (RAD 301) radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma (PDAC).
Trivehexin is a novel radiopharmaceutical aimed at imaging and treatment of pancreatic cancer by targeting αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth.
The FDA's decision offers unique incentives and benefits for the development of this drug, which hopes to improve and support early diagnosis of one of the most high-demand cancer types.

2023-05-09 09:54:00

Radiopharm Theranostics enters into a supply agreement with TerThera for Terbium-161 isotope.
Tb-161 will be used in the development of RAD 602, a potential first-in-class radiopharmaceutical for the treatment of brain cancers.
Phase I trial of RAD 602 is set to begin in the fourth quarter of 2023.

2023-04-17 09:43:00

Radiopharm Theranostics (ASX:RAD) has entered into a binding agreement to acquire Pharma15 Corporation, a private US- based venture which is developing next -generation therapeutic radiopharmaceutical s for Prostate Cancer.
The acquisition includes Professor David Ulmert and CEO Suzanne Dance, as well as KOL Professor Ken Herrmann joining RAD's Scientific Advisory Board.
The agreement includes the issue of ordinary shares and cash up -front, with some consideration deferred and some subject to the achievement of significant clinical milestones.

2023-03-03 09:37:00

Radiopharm Theranostics is initiating the process to obtain a secondary listing on the Nasdaq Capital Market.
The Company has filed a registration statement on Form 20-F with the US Securities and Exchange Commission (SEC) and a listing application with Nasdaq.
The Company expects the SEC and Nasdaq to complete their respective review processes by late March and, when their processes are successfully completed, then the listing on Nasdaq would occur.

2023-02-14 08:35:00

Radiopharm Theranostics received FDA Investigational New Drug Application (IND) approval for its αVβ6 Integrin (RAD301) technology.
The approval allows Radiopharm to begin a Phase 1 imaging trial in ambulatory patients with pancreatic cancer.
Pancreatic cancer presents a major unmet clinical need with an urgent need for new treatment options.

2022-12-30 09:58:00